Session » (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2136

Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice

9:00AM-11:00AM: Abstract Number: 2096

Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure

9:00AM-11:00AM: Abstract Number: 2127

Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer

9:00AM-11:00AM: Abstract Number: 2139

Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2134

Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA

9:00AM-11:00AM: Abstract Number: 2133

Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI

9:00AM-11:00AM: Abstract Number: 2121

Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2105

Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2125

Comparing the ITIS Diet and the Mediterranean Diet in Rheumatoid Arthritis: Preliminary Findings on Clinical and Microbiome Outcomes

9:00AM-11:00AM: Abstract Number: 2097

Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque

9:00AM-11:00AM: Abstract Number: 2098

Contribution of Rare Deleterious Exonic Variants in Telomere Related Genes to Interstitial Lung Disease Risk in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2122

Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study

9:00AM-11:00AM: Abstract Number: 2101

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

9:00AM-11:00AM: Abstract Number: 2123

Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 2106

Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls

9:00AM-11:00AM: Abstract Number: 2124

Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

9:00AM-11:00AM: Abstract Number: 2138

Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2117

Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2115

Genetic Risk Load as a Predictor of Radiographic Damage and Mortality in Female Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2128

Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2113

Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies

9:00AM-11:00AM: Abstract Number: 2120

Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections

9:00AM-11:00AM: Abstract Number: 2103

Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2095

Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2102

Is This Prosthetic Joint Infected or Flaring?

9:00AM-11:00AM: Abstract Number: 2099

Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan

9:00AM-11:00AM: Abstract Number: 2137

Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics

9:00AM-11:00AM: Abstract Number: 2118

New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry

9:00AM-11:00AM: Abstract Number: 2100

Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2126

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity

9:00AM-11:00AM: Abstract Number: 2112

Physical Activity in a Cohort of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2130

Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab

9:00AM-11:00AM: Abstract Number: 2109

Real-world Positivity of 14-3-3η Protein in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2104

Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2110

Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers

9:00AM-11:00AM: Abstract Number: 2116

Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2129

SCORE and SCORE2 Comparison in Cardiovascular Risk Estimation in Rheumatoid Arthritis Patients: A Cross-sectional Study Including Carotid Ultrasound

9:00AM-11:00AM: Abstract Number: 2111

Self-reported Methotrexate Adherence Underestimates Biochemical Adherence: Results from the Methotrexate Use Improvement in Rheumatoid Arthritis Using Biomarker Feedback Trial

9:00AM-11:00AM: Abstract Number: 2119

Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2140

Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2107

Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study

9:00AM-11:00AM: Abstract Number: 2108

Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH)

9:00AM-11:00AM: Abstract Number: 2135

Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression

9:00AM-11:00AM: Abstract Number: 2132

Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates

9:00AM-11:00AM: Abstract Number: 2114

The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function

9:00AM-11:00AM: Abstract Number: 2131

Time-course Analysis from the First Wave to Early 2023 in Critically Ill Patients with Novel Coronavirus Infection in Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].